KAPA — KAIROS PHARMA LTD
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.77 | — | -0.77 | -0.77 | 1 | — |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -2.59 | — | -2.59 | -2.59 | 1 | — |
| Dec 2027 | -4.69 | — | -4.69 | -4.69 | 1 | — |
| Dec 2028 | -5.11 | — | -5.11 | -5.11 | 1 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 6 SEC-registered investment managers reported holding KAPA (KAIROS PHARMA LTD) in their latest 13F filings, with a combined reported value of $57.80K across 35.21K shares. That is -90.4% by share count (-306.81K shares) versus the previous quarter, while reported value moved -58.9%. Ownership is concentrated: the five largest holders account for 97.1% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 opened new positions, 5 trimmed, 9 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of KAIROS PHARMA LTD (KAPA) include ARMISTICE CAPITAL, LLC, UMB Bank, n.a., Citadel Advisors, ranked by reported 13F value among the 30 institutional holders on this page.
KAPA is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 6 | 35.21K | $57.80K | -90.4% |
| Q2 2026 | 14 | 1.02M | $392.13K | -6.5% |
| Q1 2026 | 11 | 601.06K | $341.51K | -5.3% |
| Q4 2025 | 14 | 855.72K | $607.47K | +23.9% |
| Q3 2025 | 14 | 445.02K | $505.84K | +2.0% |
| Q2 2025 | 10 | 218.72K | $172.89K | +7.2% |
| Q1 2025 | 8 | 1.58M | $1.46M | -26.5% |
| Q4 2024 | 5 | 406.60K | $618.27K | -58.3% |
Over the 8 quarters shown, institutional share counts decreased 91% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q4 2024 (-58.3%).
Top Institutional Holders (Q3 2026) — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 13.60K | $22.30K | 0.00% | Reduce | |
| 9.71K | $15.92K | 0.00% | Reduce | |
| 6.87K | $11.27K | 0.00% | Reduce | |
| 2.52K | $4.18K | 0.00% | New | |
| 1.49K | $2.44K | 0.00% | Reduce | |
| 1.03K | $1.69K | 0.00% | Reduce |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 14 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 309.83K | $118.88K | 0.00% | New | |
| 231.88K | $89.04K | 0.00% | Hold | |
| 82.09K | $31.00K | 0.00% | New | |
| 78.92K | $30.28K | 0.00% | New | |
| 78.92K | $30.28K | 0.00% | Reduce | |
| 63.88K | $24.53K | 0.00% | Hold | |
| 44.29K | $17.09K | 0.00% | Hold | |
| 44.29K | $16.99K | 0.00% | Hold | |
| 33.75K | $12.95K | 0.00% | New | |
| 29.29K | $11.24K | 0.00% | New | |
| 14.92K | $5.72K | 0.00% | New | |
| 6.26K | $2.40K | 0.00% | New | |
| 3.73K | $1.43K | 0.00% | Reduce | |
| 723 | $277 | 0.00% | New |
Q1 2026 — 11 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 231.88K | $129.62K | 0.00% | New | |
| 111.29K | $62.21K | 0.00% | Add | |
| 63.88K | $35.71K | 0.00% | New | |
| 44.29K | $30.33K | 0.01% | Hold | |
| 44.29K | $24.76K | 0.00% | Hold | |
| 39.54K | $22.11K | 0.00% | Reduce | |
| 24.10K | $13.47K | 0.00% | Hold | |
| 21.57K | $12.00K | 0.00% | Add | |
| 16.25K | $9.08K | 0.00% | New | |
| 3.96K | $2.21K | 0.00% | Reduce | |
| 10 | $6 | 0.00% | New |
Q4 2025 — 14 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 321.74K | $228.43K | 0.00% | New | |
| 131.83K | $93.60K | 0.00% | Hold | |
| 94.01K | $66.75K | 0.00% | Add | |
| 72.83K | $51.71K | 0.00% | Add | |
| 48.49K | $34.43K | 0.00% | Add | |
| 44.29K | $31.89K | 0.01% | Hold | |
| 44.29K | $31.44K | 0.00% | Hold | |
| 24.10K | $17.11K | 0.00% | Hold | |
| 21.32K | $15.00K | 0.00% | New | |
| 20.28K | $14.00K | 0.00% | New | |
| 15.14K | $10.75K | 0.00% | New | |
| 13.04K | $9.26K | 0.00% | New | |
| 4.23K | $3.00K | 0.00% | Reduce | |
| 134 | $95 | 0.00% | Reduce |
Q3 2025 — 14 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 131.83K | $154.24K | 0.00% | New | |
| 65.80K | $76.98K | 0.00% | Add | |
| 45.79K | $53.57K | 0.00% | New | |
| 44.29K | $51.81K | 0.00% | Hold | |
| 44.29K | $37.65K | 0.01% | Hold | |
| 24.89K | $29.13K | 0.00% | Add | |
| 24.10K | $28.20K | 0.00% | New | |
| 23.50K | $27.00K | 0.01% | New | |
| 14.89K | $17.42K | 0.00% | New | |
| 12.41K | $14.52K | 0.00% | Reduce | |
| 5.98K | $7.00K | 0.00% | Reduce | |
| 5.96K | $6.97K | 0.00% | Add | |
| 1.00K | $1.00K | 0.00% | New | |
| 304 | $356 | 0.00% | Add |
Q2 2025 — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 44.29K | $49.60K | 0.01% | Hold | |
| 62.75K | $44.49K | 0.00% | New | |
| 44.29K | $31.40K | 0.00% | Hold | |
| 21.80K | $15.46K | 0.00% | Add | |
| 13.55K | $9.61K | 0.00% | New | |
| 13.24K | $9.00K | 0.00% | New | |
| 9.46K | $6.71K | 0.00% | Add | |
| 5.50K | $3.90K | 0.00% | New | |
| 3.80K | $2.69K | 0.00% | New | |
| 51 | $36 | 0.00% | Add |
New Positions (Q3 2026)
- Nuveen, LLC 2.52K sh · $4.18K
Fully Exited (vs previous quarter)
- Citadel Advisors sold 309.83K sh · $118.88K
- Virtu Financial LLC sold 82.09K sh · $31.00K
- GEODE CAPITAL MANAGEMENT, LLC sold 78.92K sh · $30.28K
- Geode Capital Management sold 78.92K sh · $30.28K
- SevenBridge Financial Group, LLC sold 44.29K sh · $17.09K
- Aptus Capital Advisors, LLC sold 44.29K sh · $16.99K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP sold 29.29K sh · $11.24K
- XTX Topco Ltd sold 14.92K sh · $5.72K
- BARCLAYS PLC sold 723 sh · $277
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|---|
| JANE STREET GROUP, LLC | 13.60K | 33.75K | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.71K | 231.88K | 231.88K | — | — | — | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 6.87K | 63.88K | 63.88K | — | — | — | — | — | — |
| Nuveen, LLC | 2.52K | — | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 1.49K | 3.73K | 3.96K | 4.23K | 5.96K | 3.80K | — | — | — |
| UBS Group AG | 1.03K | 6.26K | — | — | 5.98K | 9.46K | 2.79K | 10.85K | — |
| ARMISTICE CAPITAL, LLC | — | — | — | — | — | — | 1.40M | — | — |
| UMB Bank, n.a. | — | — | — | — | — | — | — | 371.12K | — |
| Citadel Advisors | — | 309.83K | — | 321.74K | — | — | 13.23K | 10.97K | — |
| Vanguard Group | — | — | — | 131.83K | 131.83K | — | — | — | — |
| Geode Capital Management | — | 78.92K | 111.29K | 72.83K | 65.80K | 21.80K | 20.43K | — | — |
| Two Sigma Investments | — | — | 39.54K | 94.01K | 45.79K | — | — | — | — |
| Aptus Capital Advisors, LLC | — | 44.29K | 44.29K | 44.29K | 44.29K | 44.29K | 44.29K | — | — |
| Virtu Financial LLC | — | 82.09K | — | 20.28K | — | — | — | 13.66K | 32.71K |
| SevenBridge Financial Group, LLC | — | 44.29K | 44.29K | 44.29K | 44.29K | 44.29K | 44.29K | — | — |
| Scientech Research LLC | — | — | — | — | — | — | 48.20K | — | — |
| XTX Topco Ltd | — | 14.92K | — | 48.49K | 12.41K | 62.75K | — | — | — |
| GEODE CAPITAL MANAGEMENT, LLC | — | 78.92K | — | — | — | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | 16.25K | — | 24.89K | 13.55K | — | — | — |
| STATE STREET CORP | — | — | 24.10K | 24.10K | 24.10K | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold KAPA?
As of 2026-Q3, 6 institutional funds reported holding KAPA (KAIROS PHARMA LTD) in SEC 13F filings, with a combined reported value of $57.80K.
How many shares of KAPA do institutions own?
13F filers reported 35.21K shares of KAPA, worth $57.80K in aggregate at the end of 2026-Q3.
Is institutional ownership of KAPA rising or falling?
Share counts moved -90.4% versus the prior quarter — distribution.
Who are the top institutional holders of KAPA?
The largest 13F holders are ARMISTICE CAPITAL, LLC, UMB Bank, n.a., Citadel Advisors, Vanguard Group, Scientech Research LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of KAIROS PHARMA LTD?
The major shareholders of KAIROS PHARMA LTD (KAPA) by reported 13F value are ARMISTICE CAPITAL, LLC, UMB Bank, n.a., Citadel Advisors, Vanguard Group, Scientech Research LLC, among 30 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.